Status:
Recruiting
Disease Site:
Skin
Diagnosis:
- Merkel Cell Carcinoma
Phase:
Official Title:
A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma
NCT ID:
NCT#03712605
Link to Full Details:
Investigators:
- Dr. Mark Olsen
Description:
This phase III trial studies how well pembrolizumab works compared to standard of care observation in treating patients with stage I-III Merkel cell cancer that has been completely removed by surgery (resected). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Eligibility:
Male and Female – 18 years and older
Inclusion Criteria:
- Age greater than or equal to 18 years
- No previous systemic therapy or XRT for MCC
- Pathologic stages of I-IIIb
Exclusion Criteria:
- Non-accessible surgical resection report
- Stage I disease w/ negative sentinel lymph nodes
- Resection date over 8 weeks from registration